GPRC5D and Miyoshi myopathy: For antigen loss identified in patients refractory to BCMA CAR T treatment, preclinical studies have demonstrated that targeting the new antigen GPRC5D using CAR-T or BiTE could still effectively induce lysis of the BCMA knockout MM cell lines [106,108].